1. Home
  2. TECX vs GOSS Comparison

TECX vs GOSS Comparison

Compare TECX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • GOSS
  • Stock Information
  • Founded
  • TECX 2019
  • GOSS 2015
  • Country
  • TECX United States
  • GOSS United States
  • Employees
  • TECX N/A
  • GOSS N/A
  • Industry
  • TECX
  • GOSS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TECX
  • GOSS Health Care
  • Exchange
  • TECX Nasdaq
  • GOSS Nasdaq
  • Market Cap
  • TECX 387.1M
  • GOSS 347.8M
  • IPO Year
  • TECX 2018
  • GOSS 2019
  • Fundamental
  • Price
  • TECX $23.51
  • GOSS $1.96
  • Analyst Decision
  • TECX Strong Buy
  • GOSS Strong Buy
  • Analyst Count
  • TECX 5
  • GOSS 4
  • Target Price
  • TECX $79.00
  • GOSS $8.50
  • AVG Volume (30 Days)
  • TECX 230.2K
  • GOSS 3.1M
  • Earning Date
  • TECX 08-07-2025
  • GOSS 08-05-2025
  • Dividend Yield
  • TECX N/A
  • GOSS N/A
  • EPS Growth
  • TECX N/A
  • GOSS N/A
  • EPS
  • TECX N/A
  • GOSS N/A
  • Revenue
  • TECX N/A
  • GOSS $40,237,000.00
  • Revenue This Year
  • TECX N/A
  • GOSS N/A
  • Revenue Next Year
  • TECX N/A
  • GOSS $63.97
  • P/E Ratio
  • TECX N/A
  • GOSS N/A
  • Revenue Growth
  • TECX N/A
  • GOSS N/A
  • 52 Week Low
  • TECX $13.70
  • GOSS $0.66
  • 52 Week High
  • TECX $61.07
  • GOSS $2.23
  • Technical
  • Relative Strength Index (RSI)
  • TECX 56.50
  • GOSS 58.35
  • Support Level
  • TECX $21.31
  • GOSS $1.67
  • Resistance Level
  • TECX $23.12
  • GOSS $2.00
  • Average True Range (ATR)
  • TECX 1.53
  • GOSS 0.17
  • MACD
  • TECX 0.13
  • GOSS -0.02
  • Stochastic Oscillator
  • TECX 71.85
  • GOSS 52.21

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: